Navigation Links
BioMarin Announces First Quarter 2009 Financial Results
Date:4/30/2009

Net Product Revenue Increase of 25% Led by Naglazyme International Expansion

Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)

NOVATO, Calif., April 30 /PRNewswire-FirstCall/ --


               Financial Highlights ($ in millions, except per share data)

    Item                                Q1 2009            Q1 2008 Comparison

    Total BioMarin Revenue              $74.0                23% increase
    Total Net Product Revenue           $71.9                25% increase
    Naglazyme Net Product Revenue       $39.4                42% increase
    Aldurazyme Net Sales by Genzyme     $36.8                No change
    Aldurazyme BioMarin Net Product
     Revenue                            $17.0                29% decrease*
    Kuvan Net Product Revenue           $15.5                168% increase
    GAAP Net Income (Loss)              $(13.2)              $1.7
    GAAP Net Income (Loss) per share    $(0.13) (basic       $0.02 (basic
                                                 and                and
                                                 diluted)           diluted)
    Non-GAAP Net Income                 $9.3                 $4.1
    Non-GAAP Net Income per share       $0.09 (basic         $0.04 (basic
                                               and                  and
                                               diluted)             diluted)

    * The decrease in Aldurazyme BioMarin net product revenue is
      attributable to the one-time transfer of a significant amount of
      Aldurazyme inventory in the first quarter of 2008 concurrent with the
      restructuring of the BioMarin/Genzyme LLC.  Total incremental product
      revenue totaled $9.5 million in the first quarter of 2008, compared to
      $2.5 million in the first quarter of 2009.  The number of patients on
      Aldurazyme therapy worldwide continues to increas
'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
2. BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
3. BioMarin to Present at the 4th Annual Citi Biotech Day
4. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
5. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
6. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Piper Jaffray Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Credit Suisse Healthcare Conference
10. BioMarin Announces Third Quarter 2008 Financial Results
11. BioMarin Corrects Information Included in Bloomberg Article
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet form ... of special anti-vascular endothelial growth factor agents given by injection into the eye. ... have a scientific protocol for the many millions diagnosed with it. AMD usually ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ... report "Gene Therapy - Technologies, Markets and Companies" ... gene therapy are difficult to estimate as there is ... marketed in China since 2004. ... The estimates are based on epidemiology of diseases to ...
(Date:9/2/2015)... September 2, 2015 Biovista Inc. ... of the 2015 BeHEARD science challenge, a global competition ... disease researchers, access to the latest life science innovations ... repositioning and pathway analytics capability to support Steven ... in the study of Niemann-Pick Disease Type A (NPA), ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Partners and Versant Ventures Lead ... Transform Clinical Microbiology, MADISON, Wis., Sept. 12 OpGen, ... equity financing. The round,was led by CHL Medical Partners, Highland ... participating. In,conjunction, CHL,s Ron Lennox will become chairman of the ...
... PHOENIX, Sept. 11 ThirdBiotech,( http://www.thirdbiotech.com ), ... has begun operations in Arizona. (Logo: ... of ThirdBiotech created the group to foster,networking ... and healthcare,community throughout the state. "It,s important ...
... LAKE CITY, Sept. 11 Dynatronics,Corporation (Nasdaq: ... quarter,and fiscal year ended June 30, 2007 during ... has scheduled a conference call for investors later ... results for the quarter and fiscal year.,Those interested ...
Cached Biology Technology:OpGen Announces $23.6 Million Series A Financing 2OpGen Announces $23.6 Million Series A Financing 3
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/12/2015)... , Aug. 12, 2015  New research unveiled ... attack Android phones to steal users, fingerprints. Information ... availability of fingerprint scanners on mobile devices, making ... To secure biometrics on mobile devices, HYPR Corp. ... these convenient authentication systems with strong cryptographic security. ...
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... in eastern U.S.,s forests before a blight wiped it out ... landscape thanks in part to work by a University of ... TIP). Once used extensively for building, for tanning ... wildlife, and even as nutritious fodder for hogs, the American ...
... (Santa Barbara, Calif.) New approaches are needed to ... environmental threats that lie ahead in the 21st century, ... The scientists propose that global biophysical boundaries, identified ... earth system, can define a "safe planetary operating space" ...
... the groundwater table has been dubbed the "Critical Zone" because ... and nutrients necessary for life. Now an interdisciplinary team ... Southwest with the help of a five-year, $4.35 million grant ... "We think of the critical zone as being a ...
Cached Biology News:Tennessee foresters helping to return chestnuts to American forests 2Scientists outline planetary boundaries: A safe operating space for humanity 2Scientists outline planetary boundaries: A safe operating space for humanity 3UA awarded $4.35 million to study Earth's critical zone 2UA awarded $4.35 million to study Earth's critical zone 3
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... Molecular Probes intensely fluorescent and highly ... for use in a variety of ... a strong signal. Unfortunately, protein- and ... that may cause them to bind ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Source: Tritirachium album Description: ... endopeptidase used in a wide range of applications ... peptide bonds mainly following the carboxyl group of ... and is classified as a serine protease. ...
Biology Products: